Annual Current Liabilities
$8.16 M
+$650.00 K+8.65%
December 31, 2023
Summary
- As of February 12, 2025, CYCC annual total current liabilities is $8.16 million, with the most recent change of +$650.00 thousand (+8.65%) on December 31, 2023.
- During the last 3 years, CYCC annual current liabilities has risen by +$5.67 million (+228.28%).
- CYCC annual current liabilities is now -45.13% below its all-time high of $14.87 million, reached on December 31, 2005.
Performance
CYCC Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$6.35 M
-$835.00 K-11.62%
September 30, 2024
Summary
- As of February 12, 2025, CYCC quarterly total current liabilities is $6.35 million, with the most recent change of -$835.00 thousand (-11.62%) on September 30, 2024.
- Over the past year, CYCC quarterly current liabilities has dropped by -$1.81 million (-22.18%).
- CYCC quarterly current liabilities is now -57.30% below its all-time high of $14.87 million, reached on December 31, 2005.
Performance
CYCC Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
CYCC Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.7% | -22.2% |
| 3 y3 years | +228.3% | -13.4% |
| 5 y5 years | +83.3% | -13.4% |
CYCC Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.8% | -23.9% | +45.9% |
| 5 y | 5-year | at high | +237.2% | -23.9% | +320.0% |
| alltime | all time | -45.1% | +237.2% | -57.3% | +320.0% |
Cyclacel Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.35 M(-11.6%) |
| Jun 2024 | - | $7.19 M(-13.9%) |
| Mar 2024 | - | $8.35 M(+2.3%) |
| Dec 2023 | $8.16 M(+8.7%) | $8.16 M(+0.2%) |
| Sep 2023 | - | $8.15 M(+20.8%) |
| Jun 2023 | - | $6.75 M(-8.1%) |
| Mar 2023 | - | $7.34 M(-2.3%) |
| Dec 2022 | $7.51 M(+38.8%) | $7.51 M(+72.5%) |
| Sep 2022 | - | $4.35 M(-13.4%) |
| Jun 2022 | - | $5.03 M(-19.0%) |
| Mar 2022 | - | $6.20 M(+14.6%) |
| Dec 2021 | $5.41 M(+117.7%) | $5.41 M(+50.7%) |
| Sep 2021 | - | $3.59 M(+15.2%) |
| Jun 2021 | - | $3.12 M(+12.5%) |
| Mar 2021 | - | $2.77 M(+11.5%) |
| Dec 2020 | $2.49 M(+2.7%) | $2.49 M(+45.2%) |
| Sep 2020 | - | $1.71 M(+13.2%) |
| Jun 2020 | - | $1.51 M(-0.7%) |
| Mar 2020 | - | $1.52 M(-37.1%) |
| Dec 2019 | $2.42 M(-45.6%) | $2.42 M(+16.9%) |
| Sep 2019 | - | $2.07 M(-17.2%) |
| Jun 2019 | - | $2.50 M(+0.5%) |
| Mar 2019 | - | $2.49 M(-44.1%) |
| Dec 2018 | $4.45 M(+8.2%) | $4.45 M(+11.2%) |
| Sep 2018 | - | $4.00 M(+0.2%) |
| Jun 2018 | - | $3.99 M(-6.2%) |
| Mar 2018 | - | $4.26 M(+3.5%) |
| Dec 2017 | $4.11 M(-21.8%) | $4.11 M(-3.6%) |
| Sep 2017 | - | $4.26 M(-1.3%) |
| Jun 2017 | - | $4.32 M(+4.6%) |
| Mar 2017 | - | $4.13 M(-21.5%) |
| Dec 2016 | $5.26 M(-8.6%) | $5.26 M(-5.6%) |
| Sep 2016 | - | $5.57 M(+0.1%) |
| Jun 2016 | - | $5.57 M(+3.1%) |
| Mar 2016 | - | $5.40 M(-6.2%) |
| Dec 2015 | $5.75 M(-23.2%) | $5.75 M(+9.3%) |
| Sep 2015 | - | $5.26 M(-18.9%) |
| Jun 2015 | - | $6.49 M(-20.2%) |
| Mar 2015 | - | $8.14 M(+8.6%) |
| Dec 2014 | $7.49 M | $7.49 M(+10.7%) |
| Sep 2014 | - | $6.77 M(-13.1%) |
| Jun 2014 | - | $7.78 M(-11.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $8.81 M(+21.4%) |
| Dec 2013 | $7.26 M(-22.3%) | $7.26 M(-19.2%) |
| Sep 2013 | - | $8.98 M(+36.5%) |
| Jun 2013 | - | $6.58 M(-9.3%) |
| Mar 2013 | - | $7.25 M(-22.3%) |
| Dec 2012 | $9.34 M(+43.7%) | $9.34 M(+27.9%) |
| Sep 2012 | - | $7.30 M(+8.2%) |
| Jun 2012 | - | $6.75 M(-0.8%) |
| Mar 2012 | - | $6.80 M(+4.7%) |
| Dec 2011 | $6.50 M(-0.6%) | $6.50 M(+9.5%) |
| Sep 2011 | - | $5.93 M(-1.7%) |
| Jun 2011 | - | $6.04 M(-11.3%) |
| Mar 2011 | - | $6.81 M(+4.3%) |
| Dec 2010 | $6.54 M(-24.0%) | $6.54 M(-18.0%) |
| Sep 2010 | - | $7.96 M(-2.3%) |
| Jun 2010 | - | $8.15 M(-14.3%) |
| Mar 2010 | - | $9.51 M(+10.7%) |
| Dec 2009 | $8.59 M(-0.4%) | $8.59 M(-7.9%) |
| Sep 2009 | - | $9.33 M(-12.7%) |
| Jun 2009 | - | $10.69 M(+25.0%) |
| Mar 2009 | - | $8.55 M(-0.9%) |
| Dec 2008 | $8.63 M(-41.4%) | $8.63 M(-12.6%) |
| Sep 2008 | - | $9.88 M(-15.0%) |
| Jun 2008 | - | $11.62 M(+3.9%) |
| Mar 2008 | - | $11.18 M(-24.0%) |
| Dec 2007 | $14.71 M(+85.7%) | $14.71 M(+35.0%) |
| Sep 2007 | - | $10.90 M(-6.4%) |
| Jun 2007 | - | $11.65 M(+77.1%) |
| Mar 2007 | - | $6.58 M(-16.9%) |
| Dec 2006 | $7.92 M(-46.7%) | $7.92 M(+21.7%) |
| Sep 2006 | - | $6.51 M(-5.3%) |
| Jun 2006 | - | $6.87 M(-37.2%) |
| Mar 2006 | - | $10.95 M(-26.4%) |
| Dec 2005 | $14.87 M(+100.7%) | $14.87 M(+77.3%) |
| Sep 2005 | - | $8.39 M(+41.7%) |
| Jun 2005 | - | $5.92 M(-21.1%) |
| Mar 2005 | - | $7.51 M(+1.3%) |
| Dec 2004 | $7.41 M(-49.6%) | $7.41 M(+61.5%) |
| Sep 2004 | - | $4.59 M(+10.1%) |
| Jun 2004 | - | $4.17 M(-10.7%) |
| Mar 2004 | - | $4.67 M(-68.3%) |
| Dec 2003 | $14.71 M | $14.71 M |
FAQ
- What is Cyclacel Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual current liabilities year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly current liabilities year-on-year change?
What is Cyclacel Pharmaceuticals annual total current liabilities?
The current annual current liabilities of CYCC is $8.16 M
What is the all time high annual current liabilities for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual total current liabilities is $14.87 M
What is Cyclacel Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, CYCC annual total current liabilities has changed by +$650.00 K (+8.65%)
What is Cyclacel Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of CYCC is $6.35 M
What is the all time high quarterly current liabilities for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly total current liabilities is $14.87 M
What is Cyclacel Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, CYCC quarterly total current liabilities has changed by -$1.81 M (-22.18%)